Urology
Volume 64, Issue 2 , Pages 323-328 , August 2004

Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: Value of short-term PSADT determinations

  • Phillip L Ross

      Affiliations

    • Division of Urology, McGill University, Montreal, Quebec, Canada
    • ,
  • Salaheddin Mahmud

      Affiliations

    • Division of Urology, McGill University, Montreal, Quebec, Canada
    • Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada
    • Department of Oncology, McGill University, Montreal, Quebec, Canada
    • ,
  • Andrew J Stephenson

      Affiliations

    • Division of Urology, McGill University, Montreal, Quebec, Canada
    • A. J. Stephenson is currently at Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, New York.
    • ,
  • Luis Souhami

      Affiliations

    • Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada
    • ,
  • Simon Tanguay

      Affiliations

    • Division of Urology, McGill University, Montreal, Quebec, Canada
    • ,
  • Armen G Aprikian

      Affiliations

    • Division of Urology, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Armen G. Aprikian, M.D., Departments of Surgery and Urology, Montreal General Hospital, Room L-8309, 1650 Cedar Avenue, Montreal QC H3G 1A4, Canada

Received 12 December 2003 ,Accepted 9 March 2004.

References 

  1. Berger AP, Spranger R, Kofler K, et al.  Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate. 2003;57:93–98
  2. Carter HB, Sauvageot J, Walsh PC, et al.  Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol. 1997;157:2206–2209
  3. Kattan MW, Eastham JA, Wheeler TM, et al.  Counseling men with prostate cancer (a nomogram for predicting the presence of small, moderately differentiated, confined tumors). J Urol. 2003;170:1792–1797
  4. Kakehi Y, Kamoto T, Shiraishi T, et al.  Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol. 2002;41:47–53
  5. Do V, Choo R, De Boer G, et al.  The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int. 2002;89:703–709
  6. Choo R, Klotz L, Danjoux C, et al.  Feasibility study (watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression). J Urol. 2002;167:1664–1669
  7. Vollmer RT, Egawa S, Kuwao S, et al.  The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma (a study of 94 Japanese men). Cancer. 2002;94:1692–1698
  8. McLaren DB, McKenzie M, Duncan G, et al.  Watchful waiting or watchful progression (prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma). Cancer. 1998;82:342–348
  9. Choo R, DeBoer G, Klotz L, et al.  PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 2001;50:615–620
  10. Stephenson AJ, Aprikian AG, Souhami L, et al.  Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology. 2002;59:652–656
  11. Pound CR, Partin AW, Eisenberger MA, et al.  Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  12. Patel A, Dorey F, Franklin J, et al.  Recurrence patterns after radical retropubic prostatectomy (clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen). J Urol. 1997;158:1441–1445
  13. Roberts SG, Blute ML, Bergstralh EJ, et al.  PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76:576–581
  14. D'Amico AV, Cote K, Loffredo M, et al.  Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002;20:4567–4573
  15. Soergel TM, Koch MO, Foster RS, et al.  Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol. 2001;166:2198–2201
  16. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer (the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume). Cancer. 1993;71:2031–2040
  17. Feinstein AR: Evaluating concordances, in Principles of Medical Statistics. New York, Chapman and Hall/CRC, 2002, pp 413–419
  18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  19. Stamey TA, Kabalin JN, McNeal JE, et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989;141:1076–1083
  20. Eastham JA, Riedel E, Scardino PT, et al.  the Polyp Prevention Trial Study Group   Variation of serum prostate-specific antigen levels (an evaluation of year-to-year fluctuations). JAMA. 2003;289:2695–2700

☆ Supported in part by the American Foundation for Urologic Disease and National Institutes of Health grant T32 82088 to A. J. Stephenson.

PII: S0090-4295(04)00337-1

doi: 10.1016/j.urology.2004.03.020

Urology
Volume 64, Issue 2 , Pages 323-328 , August 2004

Article Tools

* Image Usage & Resolution